530151-56-5

Basic information

• Product Name: Bromo-PEG2-azide
• Synonyms: Bromo-PEG2-azide;Azido-PEG3-bromide;Br-PEG2-N3;1-(2-Azidoethoxy)-2-(2-bromoethoxy)ethane
• CAS NO: 530151-56-5
• Molecular Formula: C₆H₁₂BrN₃O₂
• Molecular Weight: 238.08238
• Mol File: 530151-56-5.mol

Chemical Properties

• Appearance: /
• Solubility: Soluble in DMSO, DCM, DMF
• CAS DataBase Reference: Bromo-PEG2-azide(CAS DataBase Reference)
• NIST Chemistry Reference: Bromo-PEG2-azide(530151-56-5)
• EPA Substance Registry System: Bromo-PEG2-azide(530151-56-5)

Safety Data

• Hazardous Substances Data: 530151-56-5(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation:
Bromo-PEG2-azide is used as a crosslinking agent for bioconjugation, allowing the selective and efficient coupling of biomolecules such as proteins, peptides, and nucleic acids. The azide group facilitates Click Chemistry reactions, enabling the formation of stable and specific covalent bonds with alkyne-containing molecules.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Bromo-PEG2-azide is used as a component in the development of drug delivery systems. Its crosslinking capabilities enable the creation of stable and biocompatible nanoparticles, micelles, or hydrogels for the encapsulation and controlled release of therapeutic agents.
Used in Materials Science:
Bromo-PEG2-azide is utilized as a building block in the synthesis of novel materials with tailored properties. Its ability to participate in Click Chemistry reactions allows for the precise assembly of complex macromolecular structures, such as dendrimers, polymers, and networks with specific functionalities.
Used in Chemical Synthesis:
In organic chemistry, Bromo-PEG2-azide is employed as a synthetic intermediate for the preparation of various compounds. The bromide group's reactivity in nucleophilic substitution reactions makes it a useful starting material for the synthesis of a wide range of organic molecules, including pharmaceuticals, agrochemicals, and specialty chemicals.
Used in Diagnostics:
Bromo-PEG2-azide is used as a labeling agent in the development of diagnostic tools, such as immunoassays and molecular imaging agents. Its ability to form stable covalent bonds with target molecules through Click Chemistry allows for the specific and sensitive detection of various biomarkers and analytes.

Upstream product

• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 
• 558-13-4 carbon tetrabromide 

Downstream Products

• 252378-68-0 C₁₁H₂₂N₄O₅ 

Relevant articles and documents

Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry

The HIV-1 co-receptor CCR5 possesses sulfo-tyrosine (TYS) residues at its N-terminus (Nt) that are required for binding HIV-1 gp120 and mediating viral entry. By using a 14-residue fragment of CCR5 Nt containing two TYS residues, we recently showed that CCR5 Nt binds gp120 through a conserved region specific for TYS moieties and suggested that this site may represent a target for inhibitors and probes of HIV-1 entry. As peptides containing sulfo-tyrosines are difficult to synthesize and handle due to limited stability of the sulfo-ester moiety, we have now incorporated TYS isosteres into CCR5 Nt analogs and assessed their binding to a complex of gp120-CD4 using saturation transfer difference (STD) NMR and surface plasmon resonance (SPR). STD enhancements for CCR5 Nt peptides containing tyrosine sulfonate (TYSN) in complex with gp120-CD4 were very similar to those observed for sulfated CCR5 Nt peptides indicating comparable modes of binding. STD enhancements for phosphotyrosine-containing CCR5 Nt analogs were greatly diminished consistent with earlier findings showing sulfo-tyrosine to be essential for CCR5 Nt binding to gp120. Tyrosine sulfonate-containing CCR5 peptides exhibited reduced water solubility, limiting their use in assay and probe development. To improve solubility, we designed, synthesized, and incorporated in CCR5 Nt peptide analogs an orthogonally functionalized azido tris(ethylenoxy) l-alanine (l-ate-Ala) residue. Through NMR and SPR experiments, we show a 19-residue TYSN-containing peptide to be a functional, hydrolytically stable CCR5 Nt isostere that was in turn used to develop both SPR-based and ELISA assays to screen for inhibitors of CCR5 binding to gp120-CD4.

Synthesis and cellular properties of a 1 3 1 substituted chlorin e 6-nevirapine conjugate

The synthesis of a chlorin e6-nevirapine conjugate is reported, in which the nevirapine moiety is attached to the 131-position of chlorin e6 via a diethylene glycol linker. This conjugate was found to be nontoxic in the dark (IC50 > 200 μM), but highly phototoxic (IC50 = 0.21 μM at 1.5 J/cm2) toward human HEp2 cells. The chlorin e6-nevirapine conjugate accumulated within cells in multiple organelles, including the Golgi, lysosomes and mitochondria. On the other hand, nevirapine was found to be nontoxic to HEp2 cells.

GPX4 protein degradation agent, preparation method and application thereof, and antitumor cell drug

The invention provides a GPX4 protein degradation agent, a preparation method thereof, and an anti-tumor cell drug, and belongs to the technical field of drug application. The GPX4 protein degradation agent provided by the invention has a protein degradation targeting chimera (PROTAC) molecular structure, a mother nucleus structure of the GPX4 protein degradation agent is used as a small molecule ligand for combining target protein, an A2 substituent is used as a small molecule ligand for combining an E3 ubiquitin ligase compound, and an A1 substituent is used as a connecting group for connecting the two ligands. The GPX4 protein degradation agent with the structure can specifically recognize GPX4 protein and effectively ubiquitinate and degrade the GPX4 protein, so that tumor cell ferroptosis is induced.

Compound for targeted degradation of adhesion spot kinase and application thereof (by machine translation)

The invention belongs to the technical field of medicines, and provides a compound as shown in general formula (I) and geometric isomers or pharmaceutically acceptable salts, hydrates, solvates, prodrugs and a preparation method thereof. The compound has good degradation activity on the adhesion spot kinase (FAK). The compounds, and geometric isomers or pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof are as shown in the general formula I, wherein Y, L, X, Z, R1 What is claimed is: the claims and the description. (by machine translation)

COMPOUNDS AND METHOD OF USE

This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD 19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor ("EGFR") antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP

Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.